Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures• Rapid platform adoption with over 50 biopharma and academic partners to date, including 7 of the top 10 pharmaceutical companies

Portal Biotechnologies宣布了50多个合作伙伴关系，并超额认购了IA Ventures牵头的700万美元种子回合•迄今为止，已有50多个生物制药和学术合作伙伴（包括前10家制药公司中的7家）快速采用平台

• Oversubscribed $7M financing proceeds, coupled with revenue, to drive continued growth and launch of next generation products

•超额认购700万美元的融资收益，再加上收入，以推动下一代产品的持续增长和推出

• Anil Narasimha, Ph.D. joins as Chief Commercial OfficerCAMBRIDGE, Mass., December 19, 2024-- Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced an oversubscribed $7M seed round led by IA Ventures with participation from Pear VC, Undeterred Ventures, Page One VC, IKJ Capital and other current investors..

•Anil Narasimha博士于2024年12月19日加入马萨诸塞州剑桥市担任首席商务官——今天，细胞工程平台公司Portal Biotechnologies，Inc.（“Portal”）宣布了一轮由IA Ventures牵头的700万美元种子超额认购，Pear VC、Underred Ventures、Page One VC、IKJ Capital和其他现有投资者参与。。

Portal is implementing a simplified approach to intracellular delivery, focused on enabling novel cell engineering and analytical capabilities. The initial product suite for research and clinical scales are based on next generation mechanical delivery technology capable of delivering many different types of cargo into a broad range of cells.

门户网站正在实施一种简化的细胞内递送方法，重点是实现新的细胞工程和分析能力。用于研究和临床规模的初始产品套件基于下一代机械输送技术，能够将许多不同类型的货物输送到各种细胞中。

This simple approach has been shown to enable delivery of a variety of molecules into cells, including impermeable small molecules, polypeptides, antibodies, RNA and gene editing complexes, both individually and simultaneously, for multiplexed cell function modification..

这种简单的方法已被证明能够将多种分子递送到细胞中，包括不可渗透的小分子，多肽，抗体，RNA和基因编辑复合物，无论是单独还是同时进行多重细胞功能修饰。。

Since emerging from stealth a year ago, Portal has accumulated over 50 biopharma and academic partners leveraging the platform for applications ranging from novel drug screening assays to engineering cell therapies with circular RNA. Portal’s customer base includes 7 of the top 10 pharmaceutical companies, is a member of the Bayer Co.Lab in Cambridge, and affiliated with the Roche Accelerator in Shanghai.

自一年前从隐身中崛起以来，门户网站已经积累了50多个生物制药和学术合作伙伴，利用该平台进行从新药筛选分析到环状RNA工程细胞疗法的应用。门户网站的客户群包括前10家制药公司中的7家，是剑桥拜耳公司实验室的成员，并隶属于上海罗氏加速器。

Under the ‘Powered by Portal’ model, the company is also integrating its single-use cartridges with high throughput robotics manufacturers and clinical equipment providers..

在“门户驱动”模式下，该公司还将其一次性墨盒与高通量机器人制造商和临床设备供应商进行集成。。

“The rapid adoption of Portal’s platform has been a very exciting experience. I am deeply grateful to our investors and early adopters for their faith in us at these early stages as we build on our past experiences at MIT and SQZ to democratize access to this potentially transformative technology. As a scientist, I have loved the creativity of our partners in deploying Portal’s unique capabilities in new ways.

。

As a former cancer patient, I can’t wait to see what novel therapeutics we may enable!” said Armon Sharei, Ph.D., Founder and CEO of Portal..

作为一名前癌症患者，我迫不及待地想看看我们可以实现什么样的新疗法！”门户网站创始人兼首席执行官阿蒙·沙雷博士说。。

To further accelerate Portal’s commercial activities, while maintaining a commitment to enabling novel science and patient impact, Anil Narasimha, Ph.D. joined as Chief Commercial Officer. Dr. Narasimha was most recently a co-founder and CEO of Mekonos where he gained a deep understanding of the ex-vivo drug delivery space.

为了进一步加快门户网站的商业活动，同时保持对新科学和患者影响的承诺，Anil Narasimha博士加入首席商务官。Narasimha博士最近是Mekonos的联合创始人兼首席执行官，他对离体药物输送空间有了深入的了解。

Paired with Portal’s CEO, Armon Sharei, Ph.D, and COO, Alec Barclay, the company is well positioned to continue scaling its partnering activities and platform development to enable novel drug discovery and cell therapy capabilities across disease areas..

与门户网站首席执行官Armon Sharei博士和首席运营官Alec Barclay合作，该公司将继续扩大其合作活动和平台开发，以实现跨疾病领域的新药发现和细胞治疗能力。。

“I am extremely excited to join the Portal team,” said Anil Narasimha. “Delivery is a huge bottleneck for a variety of different applications, and Portal has a product that can solve these issues in a simple, fast, and efficient manner.”

阿尼尔·纳拉西姆哈（AnilNarasimha）表示：“能加入门户网站团队，我非常兴奋。”。“对于各种不同的应用程序来说，交付是一个巨大的瓶颈，门户网站有一种产品可以以简单、快速、高效的方式解决这些问题。”

About Portal Biotechnologies:

关于门户生物技术：

Portal is a cell engineering platform company focused on enabling next generation cell engineering and analytics across research and clinical applications. The company is implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and molecular design technologies.

门户是一家细胞工程平台公司，专注于跨研究和临床应用实现下一代细胞工程和分析。该公司正在实施一种简化的细胞内递送方法，专注于加速新一代RNA，基因编辑和分子设计技术所带来的进步。

Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The process relies on transient perturbation of a cell’s membrane as it transits through microscopic holes in a thin, specially designed, silicon surface.

门户网站的初始产品套件基于专有的机械输送系统，能够将多种不同类型的货物输送到各种细胞类型。该过程依赖于细胞膜通过特殊设计的薄硅表面上的微孔时的瞬时扰动。

The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics. For more information, please visit https://portal.bio/..

该技术能够独立使用或作为第三方系统的集成组件使用，为广泛影响生物学研究和细胞治疗领域提供了重要机会。有关更多信息，请访问https://portal.bio/..

About IA Ventures:

关于IA Ventures：

IA Ventures is an early stage venture capital firm investing in software and frontier technology companies. IA's all-partner team works directly with founders from seed to IPO. Since its founding in 2010, IA has backed more than 100 companies including Datadog, The Trade Desk, Wise, DigitalOcean, and Komodo Health.Contact: .

IA Ventures是一家早期风险投资公司，投资于软件和前沿技术公司。IA的全合伙人团队从种子到IPO都直接与创始人合作。自2010年成立以来，IA已经支持了100多家公司，包括Datadog、The Trade Desk、Wise、DigitalOcean和Komodo Health。联系人：。。

Portal Biotechnologies

Shirley Mao

毛雪莉（ShirleyMao）

shirley@portal.bio

shirley@portal.bio